Bromhexine for Post-exposure COVID-19 Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
Authors:
- Ramin TolouianRTRamin Tolouian
- Omid MoradiOMOmid Moradi
- Zuber D. MullaZMZuber D. Mulla
- Shadi ZiaieSZShadi Ziaie
- Mehrdad HaghighiMHMehrdad Haghighi
- Hadi EsmailyHEHadi Esmaily
- Hossein AminiHAHossein Amini
- Rezvan HassanpourRHRezvan Hassanpour
- Mehran KouchekMKMehran Kouchek
- Alireza Manafi-RasiAMAlireza Manafi-Rasi
- Shahnaz SaliSSShahnaz Sali
Open Access
- 7 November 2022
- journal article
- research article
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 15 (8)
Abstract
Background: Limited medications are available for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) infection. Whether bromhexine can prevent or mitigate symptomatic infection after virus exposure is undetermined. Objectives: We aimed to evaluate bromhexine's effect on preventing COVID-19 after close contact exposure. Methods: A multi-center randomized, double-blind, placebo-controlled clinical trial was conducted on 372 adults (≥ 18 years) who had close contact within four days with a household member with confirmed COVID-19. They were randomly assigned to receive bromhexine 8 mg (n = 187) or placebo (n = 185) three times a day for two weeks. The primary outcome was the incidence of symptomatic COVID-19. Secondary outcomes included hospitalization or death, confirmed COVID-19 by Polymerase Chain Reaction (PCR) in symptomatic patients, and adverse drug reactions. Results: The incidence of symptomatic COVID-19 was significantly lower in individuals who received bromhexine than in those who received the placebo (16 [8.6%] vs. 34 [18.4%], relative risk = 0.47, P = 0.005). PCR confirmation was reported in 13 (7.0%) and 26 (14.1%) individuals in the bromhexine and placebo groups, respectively (P = 0.025), with a relative risk reduction of 50%. The hospitalization rate, death, and medication side effects did not vary significantly between the bromhexine and placebo arms. Conclusions: Bromhexine is an effective, non-invasive, affordable agent with a low side-effect profile to prevent symptomatic COVID-19. Early use of bromhexine potentially provides another layer of protection; hence, it can play a role in controlling the pandemic.Keywords
This publication has 21 references indexed in Scilit:
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19New England Journal of Medicine, 2021
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) VariantNew England Journal of Medicine, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot StudyClinical and Translational Science, 2020
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19New England Journal of Medicine, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosisCurrent Opinion in Pharmacology, 2018
- Influenza virus activating host proteases: Identification, localization and inhibitors as potential therapeuticsEuropean Journal of Cell Biology, 2015